Should you buy IMMX stock?
Last updated:
Based on market data through , StockInvest.us rates Immix Biopharma, Inc. (IMMX) as a Buy Candidate with a technical score of 2.98 on its -10 to +10 scale. This is an upgrade from Sell in the previous daily evaluation.
- Buy signal since
- Price since signal Flat 0.00%
- 3-month trend forecast Up 4.07%
- +336.6% price growth over the last year
- +86.6% YTD performance
- Lower volatility than the market (beta 0.11)
Stronger technical forecast for Immix Biopharma, Inc. stock price after Monday trading
(Market data through Aug 10, 2026)
The Immix Biopharma, Inc. stock price gained 4.22% on the last trading day (Monday, 10th Aug 2026), rising from $9.72 to $10.13. During the last trading day the stock fluctuated 6.83% from a day low at $9.66 to a day high of $10.32. The price has risen in 6 of the last 10 days and is up by 16.57% over the past 2 weeks. Volume fell on the last day by -5 thousand shares and in total, 2 million shares were bought and sold for approximately $16.21 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 4.07% during the next 3 months and, with a 90% probability hold a price between $8.54 and $12.70 at the end of this 3-month period.
IMMX Signals & Forecast
Mostly positive signals in the chart today. The Immix Biopharma, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at $9.36 and $9.78. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Wednesday, July 29, 2026, and so far it has risen 23.99%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.
Support, Risk & Stop-loss for Immix Biopharma, Inc. stock
Immix Biopharma, Inc. finds support from accumulated volume at $9.98 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.660 between high and low, or 6.83%. For the last week, the stock has had daily average volatility of 7.86%.
Our recommended stop-loss: $9.79 (-3.38%) (This stock has high daily movements and this gives high risk. There is a buy signal from a pivot bottom found 8 days ago.)
Trading Expectations (IMMX) For The Upcoming Trading Day Of Tuesday 11th
For the upcoming trading day on Tuesday, 11th we expect Immix Biopharma, Inc. to open at $10.04, and during the day (based on 14 day Average True Range), to move between $9.76 and $10.50, which gives a possible trading interval of +/-$0.744 (+/-7.62%) up or down from last closing price. If Immix Biopharma, Inc. takes out the full calculated possible swing range there will be an estimated 7.62% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $9.98 (1.48%) than the resistance at $10.49 (3.55%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Earnings coming up
Immix Biopharma, Inc. will release earnings BMO on Friday, August 14, 2026.The consensus among the analysts for the expected earnings (EPS) is -$0.170. We will update the financials statements for Immix Biopharma, Inc., that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 7.63% in the first trading day after earnings release.
Is Immix Biopharma, Inc. stock A Buy?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Immix Biopharma, Inc. stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Buy candidate.
Current score:
2.978
Buy Candidate
Upgraded
Predicted Fair Opening Price
Predicted fair opening price on August 11, 2026 - $10.04 ( 0.92%).
Want to trade but not sure how?
Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* 
*Your capital is at risk
IMMX Performance
Trading levels for IMMX
Fibonacci Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 10.70 | 5.59% |
| R2 | 10.44 | 3.11% |
| R1 | 10.29 | 1.57% |
| Price | 10.13 | |
| S1 | 9.78 | -3.41% |
| S2 | 9.63 | -4.95% |
| S3 | 9.38 | -7.44% |
Accumulated Volume Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 12.02 | 18.66% |
| R2 | 11.00 | 8.59% |
| R1 | 10.49 | 3.55% |
| Price | 10.13 | |
| S1 | 9.98 | -1.48% |
| S2 | 8.72 | -13.92% |
| S3 | 8.67 | -14.41% |
FAQ
Click here for our free guide on how to buy Immix Biopharma, Inc. Stock.
Buy IMMX